Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). BioNexus Gene Lab's share price for the quarter that ended in Mar. 2024 was $0.706. BioNexus Gene Lab's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 17.67 Mil. Therefore, BioNexus Gene Lab's market cap for the quarter that ended in Mar. 2024 was $12.47 Mil.
BioNexus Gene Lab's quarterly market cap
declined
from Sep. 2023 ($15.48 Mil) to Dec. 2023 ($9.36 Mil) but then
increased
from Dec. 2023 ($9.36 Mil) to Mar. 2024 ($12.47 Mil).
BioNexus Gene Lab's annual market cap
declined
from Dec. 2021 ($364.70 Mil) to Dec. 2022 ($165.03 Mil) and
declined
from Dec. 2022 ($165.03 Mil) to Dec. 2023 ($9.36 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. BioNexus Gene Lab's Enterprise Value for Today is $3.48 Mil.
BioNexus Gene Lab Market Cap Historical Data
The historical data trend for BioNexus Gene Lab's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BioNexus Gene Lab's Market Cap
For the Specialty Chemicals subindustry, BioNexus Gene Lab's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNexus Gene Lab's Market Cap Distribution in the Chemicals Industry
For the Chemicals industry and Basic Materials sector, BioNexus Gene Lab's Market Cap distribution charts can be found below:
* The bar in red indicates where BioNexus Gene Lab's Market Cap falls into.
BioNexus Gene Lab Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
BioNexus Gene Lab's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioNexus Gene Lab (NAS:BGLC) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
BioNexus Gene Lab Market Cap Related Terms
Thank you for viewing the detailed overview of BioNexus Gene Lab's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
BioNexus Gene Lab (BioNexus Gene Lab) Business Description
BioNexus Gene Lab Corp is an emerging molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management. It focuses on developing and marketing safe, effective, and non-invasive blood tests for the early detection of diseases. The company's non-invasive blood tests analyze changes in ribonucleic acid (or RNA) to detect the potentiality of 11 different diseases. These diseases include eight cancers (nasopharyngeal, lung, liver, stomach, breast, cervical, prostate, and colon), two bowel diseases (colitis and Crohn), and osteoarthritis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BGLC has been successfully added to your 